Discontinued ProductFlunitrazepam (Cat. No. 4047) has been withdrawn from sale for commercial reasons.
Ligand at the GABAA receptor benzodiazepine modulatory site. Exhibits hypnotic effects; also displays anxiolytic and sedative properties.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Johnston et al (1998) Flunitrazepam rapidly reduces GABAA receptor subunit protein expression via a protein kinase C-dependent mechanism. Br.J.Pharmacol. 124 1338 PMID: 9723942
Merck Index 14 4146
Malanciuc et al (2009) Analytical characterization of flunitrazepam. Farmacia 57 167
View Related Products by Product Action
Keywords: Flunitrazepam, Flunitrazepam supplier, hypnotic, benzodiazepine, gabaa, receptors, modulatory, binding, sites, agonists, GABAA, Receptors, 4047, Tocris Bioscience
Citations for Flunitrazepam
Citations are publications that use Tocris products.
Currently there are no citations for Flunitrazepam.
Reviews for Flunitrazepam
There are currently no reviews for this product. Be the first to review Flunitrazepam and earn rewards!
Have you used Flunitrazepam?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GABA Receptors Scientific Review
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.